Guideline Summary: Evaluation and Management of Empty Sella Syndrome in Women with Premature Ovarian Insufficiency

Pituitary Function Assessment

• Empty sella is associated with a 29 % overall risk of hypopituitarism, and secondary adrenal insufficiency occurs in about 13.5 % of cases, which can be life‑threatening if not identified. 1
• Adrenal axis testing is the highest priority because hypocortisolism is present in 13.5 % of patients with incidentally discovered empty sella, a rate that does not differ between incidental and symptom‑driven detection. 1
• Testing algorithm: obtain a morning cortisol level; a markedly low result confirms adrenal insufficiency, whereas an intermediate value warrants an ACTH stimulation test for definitive diagnosis. 1
• Thyroid function: hypothyroidism is found in ≈29 % of clinically suspected empty sella patients (versus ≈2.8 % when the finding is incidental). Free T4 and TSH should therefore be measured. 1
• Prolactin: hyperprolactinemia occurs in ≈15.7 % of symptomatic empty sella cases and should be screened for. 1
• Growth‑hormone axis: IGF‑1 assessment reveals GH deficiency in ≈20 % of symptomatic patients compared with ≈12.5 % of incidental cases. 1
• Risk stratification: male sex, clinical suspicion, and prior traumatic brain injury increase the likelihood of hypopituitarism; however, the absence of symptoms has a limited negative predictive value (≈71 %), so testing should not be omitted based solely on symptom absence. 1
• Structural progression: conversion from a partial to a total empty sella correlates with hormonal deterioration (P = 0.006); serial neuro‑imaging and repeat hormone panels are recommended. 1

Autoimmune and Genetic Screening in POI

• Women with POI of unknown etiology should be screened for 21‑hydroxylase or adrenocortical antibodies because autoimmune adrenal insufficiency can coexist with POI. 2
• Autoimmune hypophysitis may underlie the empty sella and represent part of a broader autoimmune polyendocrine syndrome; appropriate antibody testing is therefore warranted. 2
• Thyroid autoimmunity: measurement of thyroid peroxidase and thyroglobulin antibodies is recommended given the strong association between POI and autoimmune thyroid disease. 2
• Genetic evaluation: testing for the fragile‑X (FMR1) premutation should be offered to all women with POI, with pre‑test counseling about familial implications. 2

Hormone Replacement Recommendations

• Physiologic estrogen therapy should be continued until the average age of natural menopause (≈51 years) in women with POI. 3
• In POI patients who experience migraine with aura, transdermal 17β‑estradiol (50–100 µg/24 h) is preferred over oral formulations to reduce thrombotic risk. 3
• Hormone replacement for POI should aim for physiologic estrogen doses, not contraceptive‑level dosing; approximately 5–10 % of POI patients retain residual fertility. 3

Monitoring and Follow‑Up

• Annual reassessment of pituitary function is advised when any baseline abnormality is detected; about 3 % of patients experience worsening pituitary dysfunction over time even without adenoma growth. 1
• Serial imaging is indicated for patients with a partial empty sella, as progression can precipitate further hormonal decline. 1

Critical Pitfalls

• Do not assume normal pituitary function solely because the patient lacks symptoms; the negative predictive value of symptom absence is only ≈71 % in empty sella cases. 1
• Do not overlook adrenal insufficiency, which occurs at comparable rates in incidental (≈13.5 %) and symptomatic (≈17.7 %) empty sella presentations and can be life‑threatening if missed. 1